BioWorld Today: ACC Roundup - Esperion Therapeutics, Inc.

March 27, 2012 - BioWorld Today

Esperion Therapeutics Inc., of Plymouth, Mich., presented data from a randomized, double-blind Phase II trial in 177 dyslipidemic patients showing that ETC-1002 was well tolerated and decreased LDL-C levels up to 27 percent after two weeks of treatment. The LDL-C reduction was sustained over the remaining 10 weeks of the study, and other biomarkers including Apo B, LDL-P (NMR) and nonHDL-C were significantly decreased. ETC-1002 is a smallmolecule activator of AMP kinase.